As a leading radiopharmaceutical manufacturer in Australia and New Zealand, our mission at Cyclotek is to improve patient outcomes with accessible targeted radiopharmaceuticals. Our novel PET-tracers provide patient-specific insights into their disease state, providing earlier diagnosis, more accurate assessment of disease extent and improved treatment planning and motoring. Cyclotek offers a range of radiopharmaceutical products in oncology and neurology, bringing patient-centred diagnostics to life. With the unlocking of the human genome and ever more sophisticated chemistry innovation, we seek to advance therapeutic discovery, further refine diagnostic pathways and drive higher standards in personalised medicine.